Page 10 - Read Online

Page 85 Giovannetti et al. Cancer Drug Resist 2018;1:82-6 I http://dx.doi.org/10.20517/cdr.2018.05

and schedule as well as the development of new technologies to decipher drug sensitivity and/or resistance
which might be applied to the patient before and during treatment, using samples from surrogate tissues,
including liquid biopsies.

DECLARATIONS
Authors’ contributions
Manuscript writing: Giovannetti E
Manuscript revision: Rodriguez JA

Financial support and sponsorship
None.

Conflicts of interest
There are no conflicts of interest.

Patient consent
Not applicable.

Ethics approval
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol
2009;6:259-65.
2. Park SR, Davis M, Doroshow JH, Kummar S. Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin
Oncol 2013;10:154-68.
3. Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M. Immunotherapy in NSCLC: a
promising and revolutionary weapon. Adv Exp Med Biol 2017;995:97-125.
4. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann
CE, Menssen HD, Kantarjian H, O’Brien SG, Druker BJ; IRIS Investigators. Long-term outcomes of imatinib treatment for chronic
myeloid leukemia. N Engl J Med 2017;376:917-27.
5. Van Der Steen N, Deben C, Deschoolmeester V, Wouters A, Lardon F, Rolfo C, Germonpré P, Giovannetti E, Peters GJ, Pauwels P.
Better to be alone than in bad company: the antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung
cancer. World J Clin Oncol 2016;7:425-32.
6. Codacci-Pisanelli G, Frati L, Mini E. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target! J
Chemother 2011;23:245-6.
7. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim
WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ,
Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition
in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
8. Amirouchene-Angelozzi N, Swanton C, Bardelli A. Tumor evolution as a therapeutic target. Cancer Discov 2017; doi: 10.1158/2159-
8290.CD-17-0343.
9. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD,
Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-
cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004;22:785-94.
10. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U,
Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in
advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004;22:777-84.
11. Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.New developments in the management of non-small-cell
lung cancer, focus on rociletinib: what went wrong? Onco Targets Ther 2016;9:6065-74.